These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Little PR, King VL, Davis KR, Cosgrove SB, Stegemann MR. Vet Dermatol; 2015 Feb; 26(1):23-30, e7-8. PubMed ID: 25496303 [Abstract] [Full Text] [Related]
3. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Gadeyne C, Little P, King VL, Edwards N, Davis K, Stegemann MR. Vet Dermatol; 2014 Dec; 25(6):512-8, e86. PubMed ID: 25109820 [Abstract] [Full Text] [Related]
4. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Cosgrove SB, Wren JA, Cleaver DM, Martin DD, Walsh KF, Harfst JA, Follis SL, King VL, Boucher JF, Stegemann MR. Vet Dermatol; 2013 Oct; 24(5):479-e114. PubMed ID: 23829933 [Abstract] [Full Text] [Related]
6. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study. Simpson AC, Schissler JR, Rosychuk RAW, Moore AR. Vet Dermatol; 2017 Oct; 28(5):485-e113. PubMed ID: 28513001 [Abstract] [Full Text] [Related]
8. A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood-induced hypersensitivity dermatitis. Noli C, Matricoti I, Schievano C. Vet Dermatol; 2019 Apr; 30(2):110-e30. PubMed ID: 30656750 [Abstract] [Full Text] [Related]
9. A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs. Schäfer L, Thom N. Vet Dermatol; 2024 Aug; 35(4):408-417. PubMed ID: 38465482 [Abstract] [Full Text] [Related]
10. A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA. Souza CP, Rosychuk RAW, Contreras ET, Schissler JR, Simpson AC. Vet Dermatol; 2018 Dec; 29(6):489-e164. PubMed ID: 30141223 [Abstract] [Full Text] [Related]
11. A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs. Marsella R, Ahrens K. Vet Dermatol; 2018 Oct; 29(5):439-e146. PubMed ID: 29926994 [Abstract] [Full Text] [Related]
15. Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs. Marsella R, Ahrens K, Wilkes R, Trujillo A, Dorr M. Vet Dermatol; 2020 Aug; 31(4):284-e69. PubMed ID: 32301565 [Abstract] [Full Text] [Related]
16. Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs. Denti D, Caldin M, Ventura L, De Lucia M. Vet Dermatol; 2022 Apr; 33(2):149-e42. PubMed ID: 35014745 [Abstract] [Full Text] [Related]
17. Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response. Carrasco I, Ferrer L, Puigdemont A. J Feline Med Surg; 2022 Aug; 24(8):787-793. PubMed ID: 34612749 [Abstract] [Full Text] [Related]